Author:
Henningfield J.E.,Belouin S.J.
Funder
National Institutes of Health
Reference19 articles.
1. Psychedelics: where we are now, why we got here, what we must do;Belouin;Neuropharmacology,2018
2. Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines;Belouin;Neuropharmacology,2022
3. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial;Bogenschutz;JAMA Psychiatr.,2022
4. Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder,2024
5. Considerations in assessing the abuse potential of psychedelics during drug development;Calderon;Neuropharmacology,2023